secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001171843-23-001426
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Q4 revenue up 11% to $39.6M; net loss $4.9M; FY2023 guidance $158-163M
----------------------------------------------------------------------------

- Q4 revenue $39.6M (+11% YoY); OA Pain Mgmt $23.7M (+20%), Joint Preservation $14.3M (+8%).
- Q4 net loss ($4.9M) or ($0.34) per share; adjusted net loss ($3.0M) or ($0.21) per share.
- Full year 2022 revenue $156.2M (+6%); net loss ($14.9M) vs net income $4.1M in 2021.
- FY2023 revenue guidance $158-163M (1-4% growth); OA Pain Mgmt $93.5-96M, Joint Preservation $55.5-58M.
- Hyalofast Phase III trial 199/200 enrolled; Cingal engaging FDA; RevoMotion limited release initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/f8k_030623.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-001426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer